Editas Medicine, Inc. (EDIT) News
Filter EDIT News Items
EDIT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EDIT News Highlights
- EDIT's 30 day story count now stands at 16.
- Over the past 29 days, the trend for EDIT's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- RARE, AERI and BASE are the most mentioned tickers in articles about EDIT.
Latest EDIT News From Around the Web
Below are the latest news stories about Editas Medicine Inc that investors may wish to consider to help them evaluate EDIT as an investment opportunity.
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue EstimatesEditas (EDIT) delivered earnings and revenue surprises of 21.79% and 181.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business UpdatesEDIT-101 Phase 1/2 BRILLIANCE trial enrolling mid-dose pediatric cohort; clinical data update expected in 2H 2022 EDIT-301 remains on track to dose first sickle cell disease patient in 1H 2022 and first TDT patient in 2022 EDIT-103 for RHO-adRP and EDIT-202 for solid tumors advancing towards IND-enabling studies CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for t |
Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & MoreLet us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24. |
10 Genomics Stocks in Cathie Wood’s Portfolio That Are UnderperformingIn this article, we discuss 10 genomics stocks in Cathie Wood’s portfolio that are underperforming. If you want to skip our detailed analysis of these stocks, go directly to 5 Genomics Stocks in Cathie Wood’s Portfolio That Are Underperforming. ARK Investment Management is an innovation-focused hedge fund that is headquartered in St. Petersburg, Florida, with […] |
Prothena (PRTA) Reports Q4 Loss, Tops Revenue EstimatesProthena (PRTA) delivered earnings and revenue surprises of 4.05% and 324.64%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Will Editas Medicine (EDIT) Report Negative Earnings Next Week? What You Should KnowEditas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate UpdateCAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 24, 2022, at 8:00 a.m. ET to provide a corporate update and results for the fourth quarter and full year 2021. To access the conference call: U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921 approximately five minutes before the call begins.Participa |
Editas Medicine (EDIT) Gets a Hold Rating from Leerink PartnersE ratio of…. |
Ultragenyx's (RARE) Q4 Earnings & Revenues Miss EstimatesUltragenyx (RARE) reports wider-than-expected loss in the fourth quarter of 2021 while revenues miss estimates. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayGood morning! |